InspireMD Inc. (NSPR): Price and Financial Metrics


InspireMD Inc. (NSPR): $3.66

0.06 (+1.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NSPR POWR Grades


  • Sentiment is the dimension where NSPR ranks best; there it ranks ahead of 84.18% of US stocks.
  • The strongest trend for NSPR is in Growth, which has been heading down over the past 44 weeks.
  • NSPR ranks lowest in Quality; there it ranks in the 1st percentile.

NSPR Stock Summary

  • InspireMD Inc's market capitalization of $29,077,369 is ahead of only 3.36% of US-listed equities.
  • In terms of volatility of its share price, NSPR is more volatile than 97.81% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NSPR comes in at -134.48% -- higher than that of merely 1.55% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to InspireMD Inc are RCEL, AMSC, NURO, MBII, and SFET.
  • Visit NSPR's SEC page to see the company's official filings. To visit the company's web site, go to www.inspiremd.com.

NSPR Valuation Summary

  • NSPR's price/sales ratio is 11.3; this is 197.37% higher than that of the median Healthcare stock.
  • NSPR's price/sales ratio has moved NA NA over the prior 126 months.
  • Over the past 126 months, NSPR's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for NSPR.

Stock Date P/S P/B P/E EV/EBIT
NSPR 2021-08-31 11.3 0.9 -2.8 0.4
NSPR 2021-08-30 11.2 0.9 -2.8 0.4
NSPR 2021-08-27 11.3 0.9 -2.8 0.4
NSPR 2021-08-26 9.8 0.8 -2.4 0.7
NSPR 2021-08-25 10.2 0.8 -2.5 0.6
NSPR 2021-08-24 10.2 0.8 -2.5 0.6

NSPR Growth Metrics

  • Its 4 year price growth rate is now at -100%.
  • Its 2 year net cashflow from operations growth rate is now at -21.33%.
  • The 2 year price growth rate now stands at -98.83%.
NSPR's revenue has moved up $963,000 over the prior 70 months.

The table below shows NSPR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 3.273 -12.509 -14.674
2021-06-30 3.182 -11.413 -12.836
2021-03-31 2.457 -10.368 -11.809
2020-12-31 2.485 -9.081 -10.544
2020-09-30 3.34 -8.449 -9.248
2020-09-30 3.34 -8.449 -9.248

NSPR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NSPR has a Quality Grade of F, ranking ahead of 2.38% of graded US stocks.
  • NSPR's asset turnover comes in at 0.099 -- ranking 153rd of 186 Medical Equipment stocks.
  • NEPH, PODD, and COO are the stocks whose asset turnover ratios are most correlated with NSPR.

The table below shows NSPR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.099 0.087 -4.886
2021-03-31 0.099 -0.043 -5.025
2020-12-31 0.170 0.033 -4.722
2020-09-30 0.264 0.219 -4.531
2020-09-30 0.264 0.219 -4.531
2020-06-30 0.283 0.170 -4.563

NSPR Price Target

For more insight on analysts targets of NSPR, see our NSPR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.50 Average Broker Recommendation 1.5 (Moderate Buy)

NSPR Stock Price Chart Interactive Chart >

Price chart for NSPR

NSPR Price/Volume Stats

Current price $3.66 52-week high $22.20
Prev. close $3.60 52-week low $3.45
Day low $3.48 Volume 104,300
Day high $3.66 Avg. volume 673,745
50-day MA $4.03 Dividend yield N/A
200-day MA $6.00 Market Cap 29.56M

InspireMD Inc. (NSPR) Company Bio


InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. is headquartered in Tel Aviv, Israel.


NSPR Latest News Stream


Event/Time News Detail
Loading, please wait...

NSPR Latest Social Stream


Loading social stream, please wait...

View Full NSPR Social Stream

Latest NSPR News From Around the Web

Below are the latest news stories about InspireMD Inc that investors may wish to consider to help them evaluate NSPR as an investment opportunity.

We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 22, 2021

InspireMD (NYSEAMERICAN:NSPR) Issues Earnings Results

InspireMD (NYSEAMERICAN:NSPR) posted its earnings results on Tuesday. The medical equipment provider reported ($0.53) EPS for the quarter, topping analysts consensus estimates of ($0.82) by $0.29, MarketWatch Earnings reports. InspireMD had a negative net margin of 403.39% and a negative return on equity of 47.44%. NYSEAMERICAN:NSPR opened at $4.16 on Friday. InspireMD has a 12 []

Dakota Financial News | November 12, 2021

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

-CGuard sales generated 24% YoY revenue growth-

Intrado Digital Media | November 9, 2021

InspireMD Announces Publication of 12-Month Results of CGuard EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

TEL AVIV, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its MicroNet covered stent (CGuard) versus a conventional workhorse open-cell Acculink nitinol stent were published this week. The principal investigator study was published in Journals of the American College of Cardiology (JACC) and is titled Randomized Controlled Trial of Conventional Versus MicroNet-Covered Stent in Carotid Artery Revascularization .

Intrado Digital Media | November 3, 2021

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

TEL AVIV, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its MicroNet™ covered stent (CGuard) versus a conventional “workhors

Yahoo | November 3, 2021

Read More 'NSPR' Stories Here

NSPR Price Returns

1-mo -11.81%
3-mo -18.85%
6-mo -30.94%
1-year -37.91%
3-year -97.68%
5-year -99.99%
YTD -28.42%
2020 -68.44%
2019 -86.42%
2018 -96.45%
2017 -94.88%
2016 -88.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7674 seconds.